4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kintor Pharmaceutical Limited (9939) operates in the Biotechnology industry and is headquartered in Suzhou, China with about 122 employees. Its market capitalization is roughly HK$878 million. In the fiscal year ended 2025-12-31, 9939 reported CNY 33M in revenue and (CNY 200M) in net income.
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology.
Interactive charts & full statements → Open the 9939 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 33M | CNY 5M | CNY 0M | CNY 0M | — |
| Gross Profit | CNY 8M | (CNY 5M) | (CNY 42M) | CNY 0M | — |
| Operating Income (EBIT) | (CNY 173M) | (CNY 153M) | (CNY 1.1B) | (CNY 969M) | — |
| Net Income | (CNY 200M) | (CNY 155M) | (CNY 1.1B) | (CNY 954M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 341M | CNY 515M | CNY 869M | CNY 2.1B | — |
| Total Liabilities | CNY 158M | CNY 221M | CNY 411M | CNY 560M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 9939 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms